Actively Recruiting
Phase 12 Trial Evaluating BMS-986482 Alone or With Other Therapies in Adults With Advanced Solid Tumors
Led by Bristol-Myers Squibb · Updated on 2026-10-21
286
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of BMS-986482 alone and in combination with other therapies for people with advanced solid tumors that cannot be removed or have spread. This trial includes participants who have tried other treatments but are no longer benefiting or cannot use them. The study is sponsored by Bristol-Myers Squibb and includes both early and later phase evaluations to better understand this new therapy. Participants will receive BMS-986482 either by itself or combined with other drugs at specified doses on certain days. The study is randomized with multiple experimental groups to compare different treatment approaches. The goal is to assess how well these treatments work and how safe they are for participants with advanced cancers. During the study, participants will have regular assessments to monitor side effects, measure drug levels, and evaluate tumor response using standardized criteria. Researchers will track adverse events, serious side effects, and any reasons for stopping treatment up to four years after the last dose. This long-term monitoring helps understand both short- and long-term impacts of the treatments.
CONDITIONS
Brief Title
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here